Capital Advisors Ltd’s Ginkgo Bioworks DNA Stock Holding History

Capital Advisors Ltd’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13K	Hold	1,269	–	–	﹤0.01%	790
2026 Q1	$8K	Sell	1,269 -13	-1%	-$108	﹤0.01%	869
2025 Q4	$11K	Hold	1,282	–	–	﹤0.01%	783
2025 Q3	$19K	Hold	1,282	–	–	﹤0.01%	654
2025 Q2	$14K	Sell	1,282 -3	-0.2%	-$23	﹤0.01%	703
2025 Q1	$7K	Buy	1,285 +22	+2%	+$224	﹤0.01%	847
2024 Q4	$12K	Buy	1,263 +1,247	+7,794%	+$10.7K	﹤0.01%	735
2024 Q3	$0	Buy	+16	New	+$160	﹤0.01%	1433
2022 Q4	–	Sell	-1	Closed	–	–	1309
2022 Q3	$0	Buy	+1	New	+$119	﹤0.01%	1296

Other funds holding DNA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Capital Advisors Ltd's DNA Position: Q2 2026 in Review

Capital Advisors Ltd held its Ginkgo Bioworks (DNA) position steady in Q2 2026 at 1,269 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #790.

Capital Advisors Ltd first reported a position in DNA in Q3 2022 and has held it in 9 quarters since. The position peaked at $19K in Q3 2025. 184 funds tracked by Wall St. Rank hold DNA as of Q2 2026.

Capital Advisors Ltd held 1,269 shares of Ginkgo Bioworks worth $13K as of Q2 2026.
Capital Advisors Ltd left its Ginkgo Bioworks share count unchanged in Q2 2026.
Ginkgo Bioworks made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #790 holding.
Capital Advisors Ltd first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 9 quarters since.
Capital Advisors Ltd's Ginkgo Bioworks position peaked at $19K in Q3 2025.
184 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.